Physician profile
William W Walker
NPI 1700889904
$3,286.53
in general payments reported to CMS, 2019-2025
36 companies · $85.51 in 2025
The $85.51 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $682 · 2021: $493 · 2022: $262 · 2023: $518 · 2024: $507 · 2025: $85.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $520.01 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.58 | 2019-2024 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $390.94 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Electromed, INC. | $249.98 | 2021-2025 | Smartvest |
| Insmed, INC. | $202.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $169.33 | 2019-2024 | Zerbaxa, Keytruda, Recarbrio |
| United Therapeutics Corporation | $135.38 | 2019-2021 | |
| Pharming Healthcare, INC. | $92.01 | 2023 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $90.21 | 2020-2024 | Glassia |
| Actelion Pharmaceuticals US, INC. | $84.52 | 2019-2022 | |
| Advanced Respiratory, INC | $72.70 | 2020-2021 | |
| Grifols USA, LLC | $70.21 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $66.49 | 2024 | Dupixent |
| Circassia INC. | $66.16 | 2019-2020 | |
| Philips North America LLC | $66.07 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.36 | 2023-2024 | Tezspire |
| Genentech USA, INC. | $63.00 | 2020-2021 | |
| Inari Medical, INC. | $49.26 | 2022 | |
| Pfizer INC. | $42.30 | 2023 | |
| Genzyme Corporation | $36.79 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $35.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.53 | 2019-2020 | |
| Mylan Specialty L.P. | $30.50 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $27.91 | 2024 | Ingrezza |
| Inspire Medical Systems, INC. | $24.21 | 2024 | Inspire |
| Biofire Diagnostics, LLC | $23.79 | 2019 | |
| Novo Nordisk INC | $22.90 | 2025 | Rybelsus, Ozempic |
| Covis Pharma Gmbh | $20.15 | 2023 | |
| Biogen, INC. | $17.98 | 2019 | |
| Shire North American Group INC | $17.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.69 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.56 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.06 | 2024 | Lifevest |
| Paratek Pharmaceuticals, INC. | $13.44 | 2023 | Nuzyra |
| Harmony Biosciences LLC | $13.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.